What are you looking for? Write the name, title or any keyword related to what you are looking for and select which content category it belongs to. Search Fulltext search Activities Professionals Research groups News - Any - Estudio en fase III, aleatorizado, doble ciego, controlado con placebo de Talazoparib con Enzalutamida en el cáncer de próstata metastásico resistente a la castración. Contact Protocol code: C3441021 EudraCT code: 2017-003295-31 Pathology: Tumors Principal investigator: Valderrama Rodríguez, Angelica Service: Sense classificar Phase: Fase III Recruiting: Open Status: Iniciat Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. ESTUDIO DE FASE III, ALEATORIZADO, DOBLE CIEGO DE TALAZOPARIB CON ENZALUTAMIDA FRENTE A PLACEBO CON ENZALUTAMIDA EN HOMBRES CON CÁNCER DE PRÓSTATA METASTÁSICO SENSIBLE A LA CASTRACIÓN Y CON MUTACIONES EN GENES DE REPARACIÓN DEL DAÑO EN EL ADN (TALAPRO-3) Contact Protocol code: C3441052 EudraCT code: 2021-000248-23 Principal investigator: Valderrama Rodríguez, Angelica Service: Unclassified Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio en fase I, por primera vez en seres humanos, sobre la seguridad, la farmacocinética y la eficacia preliminar de AMX-500 en participantes con cáncer de próstata resistente a la castración metastásico (CPRCm) Contact Protocol code: AMX-500-001 EudraCT code: No aplica Pathology: Tumors Principal investigator: Valderrama Rodríguez, Angelica Service: Unclassified Phase: Fase I Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Ensayo Fase I, abierto, aleatorizado, multicéntrico para investigar los efectos biológicos de AZD5305 en monoterapia, Darolutamida en monoterapia, y ambos en combinación administrados antes de la prostatectomía radical en hombres con cáncer de próstata recién diagnosticado Contact Protocol code: D9721C00002 EudraCT code: No aplica Pathology: Tumors Principal investigator: Valderrama Rodríguez, Angelica Service: Unclassified Phase: Phase I Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 1 de MOMA-313 administrado como monoterapia o en combinación con un inhibidor de la PARP en participantes con tumores sólidos avanzados o metastásicos. Contact Protocol code: MOMA-313-001 EudraCT code: No aplica Pathology: Tumors Principal investigator: Valderrama Rodríguez, Angelica Service: Unclassified Phase: Phase I Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Ensayo fase III, aleatorizado, de 2 cohortes, soble ciego, controlado con placebo de AZD5305 en combinación con un nuevo agente hormonal a elección del investigador en pacientes con cáncer de próstata metastásico hormonosensible con y sin mutación en los genes de reparación por recombinación homóloga (HRR) (EvoPar-Prostate01). Contact Protocol code: D9723C00001 EudraCT code: No aplica Pathology: Tumors Principal investigator: Valderrama Rodríguez, Angelica Service: Unclassified Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio abierto, secuencial, de búsqueda de dosis ascendentes y repetidas de sarilumab administrado con inyección subcutánea (s. c.) a niños y adolescentes con edades comprendidas entre 1 y 17 años con artritis idiopática juvenil sistémica (AIJS), seguido de una fase de extensión. Contact Protocol code: DRI13926 EudraCT code: 2015-004000-35 Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Principal investigator: Moreno Ruzafa, Estefania Research group: Reumatologia Service: Reumatologia Phase: Fase II Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio exploratorio de fase 1b, multicéntrico, aleatorizado y abierto para investigar el impacto de la administración de VH3810109 intravenoso con o sin Fostemsavir oral en combinación con terapia antirretroviral basada en inhibidores de la integrasa sobre el reservorio viral en adultos que viven con VIH-1 (ENTRANCE) Contact Protocol code: 221794 EudraCT code: No aplica Pathology: Certes afeccions originades en el període perinatal Principal investigator: Curran Fàbregas, Adria Research group: Malalties infeccioses Service: Infeccioses Phase: Phase I Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Ensayo multicéntrico, doble ciego, aleatorizado y controladocon placebo para evaluar la eficacia y seguridad de Saccharomyces boulardiiCNCM I-745 en pacientes adultos con síndrome del intestino irritable noestreñido”. Contact Protocol code: BoWell – Sb252 EudraCT code: No aplica Pathology: Malalties del sistema digestiu Principal investigator: Serra Pueyo, Jorge Research group: Fisiologia i fisiopatologia digestiva Service: Digestiu Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 1/2, multicéntrico y abierto para evaluar la seguridad, la cinética celular y la eficacia exploratoria de rapcabtagene autoleucel (YTB323) en participantes con artritis reumatoide difícil de tratar y enfermedad de Sjögren refractaria grave con afectación de órganos. Contact Protocol code: CYTB323M12101B EudraCT code: No aplica Pathology: Tumors Principal investigator: Marsal Barril, Sara Research group: Rheumatology Service: Rheumatology Phase: Phase I Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 111, aleatorizado, doble ciego y comparado conplacebo para evaluar la eficacia, la seguridad y la tolerabilidad de 2,5 mg de Bl 1291583administrados una vez al dfa durante un maxima de 76 semanas en pacientes conbronquiectasia (estudio AIRTIVITY®) Contact Protocol code: 1397-0014 EudraCT code: No aplica Pathology: Malalties del sistema respiratori Principal investigator: Polverino , Eva Research group: Pneumologia Service: Pneumologia Phase: Phase III Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad, la tolerabilidad y la farmacocinética de una dosis única ascendente y de dosis múltiples ascendentes de LTP001 en participantes adultos sanos (parte A) y para evaluar la eficacia y la seguridad de LTP001 en el tratamiento de participantes con hipertensión arterial pulmonar (parte B) Contact Protocol code: CLTP001A12202 EudraCT code: No aplica Pathology: Diseases of the respiratory system Principal investigator: Berastegui Garcia, Cristina Research group: Pneumology Service: Pneumology Phase: Phase I Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase III, aleatorizado, doble ciego y comparado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad de 2,5 mg de BI 1291583 administrados una vez al día durante un máximo de 76 semanas en pacientes con bronquiectasia (estudio AIRTIVITY®) Contact Protocol code: 1397-0014 EudraCT code: No aplica Pathology: Diseases of the respiratory system Principal investigator: Álvarez Fernandez, Antonio Research group: Pneumology Service: Pneumology Phase: Phase III Recruiting: Open Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 3b, aleatorizado, multicéntrico y comparativo entremirikizumab y placebo o mirikizumab y tirzepatida en participantes adultos con colitisulcerosa activa de moderada a grave y obesidad o sobrepeso. Contact Protocol code: I6T-MC-AMCD EudraCT code: No aplica Pathology: Digestive system diseases Principal investigator: Borruel Sainz, Natalia Research group: Physiology and Pathophysiology of the Digestive Tract Service: Digestive Phase: Phase III Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Estudio de fase 3b, aleatorizado, multicéntrico y comparativo entremirikizumab y placebo o mirikizumab y tirzepatida en participantes adultos conenfermedad de Crohn activa de moderada a grave y obesidad o sobrepeso. Contact Protocol code: I6T-MC-AMCE EudraCT code: No aplica Pathology: Digestive system diseases Principal investigator: Borruel Sainz, Natalia Research group: Physiology and Pathophysiology of the Digestive Tract Service: Digestive Phase: Phase III Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3,RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE IBUZATRELVIR INADULTS WITH SYMPTOMATIC COVID-19 WHO ARE SEVERELYIMMUNOCOMPROMISED Contact Protocol code: C5091018 EudraCT code: No aplica Pathology: Certes malalties infeccioses i parasitàries Principal investigator: Len Abad, Oscar Research group: Infectious Diseases Service: Infectious Phase: Phase III Recruiting: Closed Status: Open Contact Form Name* First surname* Second surname Email address* Telephone* Write your question* I have read and accept the data protection policy *. I have read and accept the data protection policy *. CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.Purpose: Request for information on VHIR clinical research.Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information The request for information on a research project or clinical trial does not entail inclusion in it. Year 2025 Títol Complet Servicio de secuenciación de librerias pre-elaboradas a partir de CFDNA a cargo del Proyecto PI24/00526, destinado al Grupo de Tumores Gastrointestinales y Endocrinos superiores de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR) Expedient SECUENCIACIÓN DE LIBRERIAS (PI24/00526) Codi 24987314 Data publicació Wed, 10 Sep 2025 - 12:00 Documentos (enllaços) ANUNCIO DE LICITACIÓN PLIEGO DE CLÁUSULAS ADMINISTRATIVAS PARTICULARES ANEXO 1 PCAP PLIEGO DE PRESCRIPCIONES TÉCNICAS DEUC DEUC FORMATO XML INSTRUCCIONES PARA RELLENAR EL DEUC ACUERDO DE NECESIDAD CERTIFICADO DE EXISTENCIA DE CRÉDITO RESOLUCIÓN DE APROBACIÓN DEL EXPEDIENTE RESOLUCIÓN DESIGNACIÓN MESA DE CONTRATACIÓN INFORME DE VALORACIÓN TÉCNICA ACTA OBERTURA SOBRE NÚM. 3 REQUERIMIENTO ACUERDO DE ADJUDICACIÓN Professionals Irene Bello Rodríguez - Year 2025 Títol Complet Serveis de redacció de projecte i direcció d'obra (DO) de les obres de reestructuració de la Planta 13 i 14 del Hospital de la Dona de la Fundació Hospital Universitari Vall d’Hebron - Institut de Recerca (VHIR). Expedient SERVEIS DE REDACCIÓ DE PROJECTE I DIRECCI Codi 24987657 Data publicació Fri, 3 Oct 2025 - 12:00 Documentos (enllaços) ANUNCI DE LICITACIÓ PLEC DE CLÀUSULES ADMINISTRATIVES PARTICULARS ANNEX 1 PCAP PLEC DE PRESCRIPCIONS TÈCNIQUES ANNEX 1. PLÀNOLS AMB L'ÀMBIT DEL PROJECTE ANNEX 2. PLÀNOLS EDIFICI EN PDF I DWG ANNEX 3. PLA FUNCIONAL PRINCIPALS PUNTS SOBRE DIGITAL DEUC DEUC FORMAT XML INSTRUCCIONS PER EMPLENAR EL DEUC ACORD DE NECESSITAT CERTIFICAT D'EXISTÈNCIA DE CRÈDIT RESOLUCIÓ APROVACIÓ DE L'EXPEDIENT RESOLUCIÓ DESIGNACIÓ MESA DE CONTRACTACIÓ RESOLUCIÓ D’ESMENA D’ACLARIMENT INFORME DE VALORACIÓ TÈCNICA ACTA SOBRE NÚM. 3 PROPOSTA D'ADJUDICACIÓ PROVISIONAL I REQUERIMENT ACORD D'ADJUDICACIÓ Year 2025 Títol Complet Servei de manteniment dels equips de comunicacions, gestionat per la Unitat IT, de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR) Expedient MANT. EQUIPS COMUNICACIONS Codi 24987658 Data publicació Fri, 3 Oct 2025 - 12:00 Documentos (enllaços) ANUNCI DE LICITACIÓ PLEC DE CLÀUSULES ADMINISTRATIVES PARTICULARS ANNEX 1 PCAP PLEC DE PRESCRIPCIONS TÈCNIQUES ACORD DE NECESSITAT CERTIFICAT D'EXISTÈNCIA DE CRÈDIT RESOLUCIÓ APROVACIÓ DE L'EXPEDIENT RESOLUCIÓ DESIGNACIÓ MESA DE CONTRACTACIÓ PRINCIPALS PUNTS SOBRE DIGITAL DEUC DEUC FORMAT XML INSTRUCCIONS PER EMPLENAR EL DEUC INFORME DE VALORACIÓ TÈCNICA ACTA OBERTURA SOBRE NÚM. 2 PROPOSTA D'ADJUDICACIÓ PROVISIONAL I REQUERIMENT Pagination First page « Previous page ‹ … Page 308 Page 309 Current page 310 Page 311 Page 312 … Next page › Last page »
Year 2025 Títol Complet Servicio de secuenciación de librerias pre-elaboradas a partir de CFDNA a cargo del Proyecto PI24/00526, destinado al Grupo de Tumores Gastrointestinales y Endocrinos superiores de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR) Expedient SECUENCIACIÓN DE LIBRERIAS (PI24/00526) Codi 24987314 Data publicació Wed, 10 Sep 2025 - 12:00 Documentos (enllaços) ANUNCIO DE LICITACIÓN PLIEGO DE CLÁUSULAS ADMINISTRATIVAS PARTICULARES ANEXO 1 PCAP PLIEGO DE PRESCRIPCIONES TÉCNICAS DEUC DEUC FORMATO XML INSTRUCCIONES PARA RELLENAR EL DEUC ACUERDO DE NECESIDAD CERTIFICADO DE EXISTENCIA DE CRÉDITO RESOLUCIÓN DE APROBACIÓN DEL EXPEDIENTE RESOLUCIÓN DESIGNACIÓN MESA DE CONTRATACIÓN INFORME DE VALORACIÓN TÉCNICA ACTA OBERTURA SOBRE NÚM. 3 REQUERIMIENTO ACUERDO DE ADJUDICACIÓN
Year 2025 Títol Complet Serveis de redacció de projecte i direcció d'obra (DO) de les obres de reestructuració de la Planta 13 i 14 del Hospital de la Dona de la Fundació Hospital Universitari Vall d’Hebron - Institut de Recerca (VHIR). Expedient SERVEIS DE REDACCIÓ DE PROJECTE I DIRECCI Codi 24987657 Data publicació Fri, 3 Oct 2025 - 12:00 Documentos (enllaços) ANUNCI DE LICITACIÓ PLEC DE CLÀUSULES ADMINISTRATIVES PARTICULARS ANNEX 1 PCAP PLEC DE PRESCRIPCIONS TÈCNIQUES ANNEX 1. PLÀNOLS AMB L'ÀMBIT DEL PROJECTE ANNEX 2. PLÀNOLS EDIFICI EN PDF I DWG ANNEX 3. PLA FUNCIONAL PRINCIPALS PUNTS SOBRE DIGITAL DEUC DEUC FORMAT XML INSTRUCCIONS PER EMPLENAR EL DEUC ACORD DE NECESSITAT CERTIFICAT D'EXISTÈNCIA DE CRÈDIT RESOLUCIÓ APROVACIÓ DE L'EXPEDIENT RESOLUCIÓ DESIGNACIÓ MESA DE CONTRACTACIÓ RESOLUCIÓ D’ESMENA D’ACLARIMENT INFORME DE VALORACIÓ TÈCNICA ACTA SOBRE NÚM. 3 PROPOSTA D'ADJUDICACIÓ PROVISIONAL I REQUERIMENT ACORD D'ADJUDICACIÓ
Year 2025 Títol Complet Servei de manteniment dels equips de comunicacions, gestionat per la Unitat IT, de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR) Expedient MANT. EQUIPS COMUNICACIONS Codi 24987658 Data publicació Fri, 3 Oct 2025 - 12:00 Documentos (enllaços) ANUNCI DE LICITACIÓ PLEC DE CLÀUSULES ADMINISTRATIVES PARTICULARS ANNEX 1 PCAP PLEC DE PRESCRIPCIONS TÈCNIQUES ACORD DE NECESSITAT CERTIFICAT D'EXISTÈNCIA DE CRÈDIT RESOLUCIÓ APROVACIÓ DE L'EXPEDIENT RESOLUCIÓ DESIGNACIÓ MESA DE CONTRACTACIÓ PRINCIPALS PUNTS SOBRE DIGITAL DEUC DEUC FORMAT XML INSTRUCCIONS PER EMPLENAR EL DEUC INFORME DE VALORACIÓ TÈCNICA ACTA OBERTURA SOBRE NÚM. 2 PROPOSTA D'ADJUDICACIÓ PROVISIONAL I REQUERIMENT
